Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity.
Sign Up to like & getrecommendations! Published in 2018 at "JCI insight"
DOI: 10.1172/jci.insight.96753
Abstract: Anthracyclines such as doxorubicin are highly effective chemotherapy agents used to treat many common malignancies. However, their use is limited by cardiotoxicity. We previously identified visnagin as protecting against doxorubicin toxicity in cardiac but not… read more here.
Keywords: highly potent; visnagin; doxorubicin cardiotoxicity; potent visnagin ... See more keywords